Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Splicing01:32

RNA Splicing

53.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
53.1K
RNA Splicing01:32

RNA Splicing

15.8K
15.8K
Alternative RNA Splicing02:18

Alternative RNA Splicing

20.4K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
20.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

6.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Lineage Commitment01:21

Lineage Commitment

3.4K
Commitment is the  process whereby stem cells:
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias.

Cancer discovery·2026
Same author

A post-translational regulatory map of chronic antigen-driven human T cell dysfunction.

bioRxiv : the preprint server for biology·2026
Same author

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis.

Nature genetics·2026
Same author

Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators.

Science advances·2026
Same author

Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation.

Science (New York, N.Y.)·2026
Same author

The Link between Modifiable Risk Factors and Myeloid Disorders-From Plate to Pathogenesis.

Blood cancer discovery·2025
Same journal

BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Blood cancer discovery·2026
Same journal

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

Blood cancer discovery·2026
Same journal

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026
Same journal

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same journal

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026
Same journal

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.4K

Outstanding Questions to Understand and Target Splicing Factor-Mutant Blood Cancers.

Maxim I Maron1, Omar Abdel-Wahab1

  • 1Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.

Blood Cancer Discovery
|April 21, 2026
PubMed
Summary
This summary is machine-generated.

Mutations in RNA splicing factor genes frequently occur in blood cancers like myeloid malignancies and chronic lymphocytic leukemia. Research is exploring their causal role and developing targeted therapies for these common mutations.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

8.3K
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

16.0K

Related Experiment Videos

Last Updated: Apr 23, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.4K
Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

8.3K
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

16.0K

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Mutations in RNA splicing factor genes are prevalent in myeloid malignancies and chronic lymphocytic leukemia.
  • These mutations are frequently observed in blood cancer patients, indicating a significant role in disease pathogenesis.

Purpose of the Study:

  • To discuss critical unanswered questions regarding the causal role of RNA splicing factor mutations in blood cancers and precursor conditions.
  • To highlight ongoing efforts in developing targeted therapies for these high-frequency neomorphic mutations.

Main Methods:

  • This commentary synthesizes current knowledge and expert opinion.
  • It reviews existing literature on RNA splicing factor mutations in hematologic malignancies.
  • It discusses therapeutic strategies targeting these mutations.

Main Results:

  • The commentary identifies key knowledge gaps concerning the direct causal link between splicing factor mutations and blood cancer development.
  • It underscores the therapeutic potential of targeting neomorphic mutations arising from splicing factor gene alterations.

Conclusions:

  • Further research is crucial to elucidate the precise mechanisms by which splicing factor mutations drive hematologic malignancies.
  • Targeted therapies hold promise for treating patients with these common genetic alterations in blood cancers.